As Novo Nordisk and Eli Lilly struggle to keep up with soaring demand for their popular diabetes and weight loss drugs, healthcare companies are introducing supply trackers to help patients navigate ongoing shortages.

Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.

As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.

Patients struggling to find doses of blockbuster anti-obesity and diabetes drugs will have new help from a drug supply tracker built by telehealth company Ro. Why it matters: Explosive demand for drugs from Novo Nordisk and Eli Lilly have led to shortages,